TABLE 1.

HIV-1-specific CD8+ T-cell epitopes targeted in subject AC-04

EpitopePeptide sequenceNo. of SFC/106 PBMCaSequence variationb
A11-AK11 Gag349-359ACQGVGGPGHK1,280ACQGVGGPGHK
--------S--
A2-AL9 Vpr59-67ALIRILQQL950ALIRILQQL
--t-S----c
Cw12-CC8 Tat30-37CCFHCQVC750CCFHCQVC
--M-----
Cw5-SL9 Rev67-75SAEPVPLQL1,000SAEPVPLQL
----G----
B44-AW11 Gag306-316AEQASQDVKNW2,310None
A11-AK9 Pol314-322AIFQSSMTK640None
A11-QK9 Pol425-433QIYAGIKVK530None
A11-IK10 Pol497-506IYQEPFKNLK730None
A11-QK9 Pol676-684QIIEQLIKK320None
B18-LY10 Vif102-110LADQLIHLHY1,930None
A11-QK10 Nef73-82QVPLRPMTYK820None
A11-AK9 Nef84-92AVDLSHFLK2,129None
B18-YY9 Nef135-143YPLTFGWCY240None
A2-LV10 Nef137-146LTFGWCFKLV250None
  • a Peak epitope-specific IFN-γ CD8+ T-cell responses (SFC/106 PBMC).

  • b Autologous viral sequences during primary infection (day 55 pp) and day 2,227 pp. Dashes indicate parts of sequences that match those of the lines above.

  • c A lowercase letter indicates a mixed-based population at that residue.